Working Paper |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
Basic, applied research, and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
15 |
Comparing Organizational Structures in Health Services |
0 |
0 |
0 |
0 |
1 |
1 |
7 |
2,385 |
Comparing approval procedures for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
18 |
Demand versus Supply Side Cost-Sharing: Patients’ preferences |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
Demand versus Supply Side Cost-Sharing: The users' perspective |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
14 |
Demand versus Supply Side Cost-Sharing: The users' perspective |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
19 |
Des « Nobels » de sciences économiques au service des systèmes de santé |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
11 |
Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan? |
0 |
0 |
0 |
7 |
0 |
0 |
3 |
87 |
Drug approval decision times, international reference pricing and access to new drugs |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
15 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
28 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
28 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
26 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
1 |
3 |
11 |
0 |
2 |
16 |
50 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
24 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
6 |
1 |
1 |
8 |
46 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
32 |
Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
27 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
18 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
1 |
3 |
13 |
33 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
17 |
0 |
0 |
2 |
80 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
39 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
22 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
18 |
Drug launch timing and international reference pricing |
0 |
0 |
0 |
33 |
0 |
0 |
3 |
59 |
Enjeux tarifaires de la médecine génomique |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
15 |
External Reference Pricing and Sequential Launching of Drugs |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
27 |
External referencing and pharmaceutical price negotiation |
0 |
1 |
4 |
5 |
0 |
2 |
10 |
26 |
External referencing and pharmaceutical price negotiation |
0 |
0 |
0 |
148 |
0 |
0 |
4 |
448 |
External referencing and pharmaceutical price negotiation |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
26 |
GPs’ Payment Contracts and their Referral Policy |
0 |
0 |
0 |
13 |
2 |
3 |
8 |
84 |
Health Services: Incentives and Access. Keynote speech |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
17 |
Health services: Incentives and access |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
14 |
Healthcare providers’ payments with personalized medicine |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
6 |
How Should Donors Give Foreign Aid? Project Aidversus Budget Support |
0 |
0 |
0 |
62 |
1 |
3 |
8 |
355 |
How should donors give foreign aid ? A theoretical comparison of aid modalities |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
16 |
How should donors give foreign aid? Project aid versus budget support |
0 |
0 |
1 |
110 |
1 |
2 |
7 |
270 |
How should donors give foreign aid? Project aid versus budget support |
1 |
3 |
3 |
169 |
3 |
7 |
13 |
625 |
Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
29 |
Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
17 |
0 |
2 |
4 |
37 |
Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
20 |
Incentives to patients versus incentives to health care providers: The users’ perspective |
0 |
0 |
0 |
26 |
0 |
5 |
11 |
54 |
La Médecine personnalisée |
0 |
0 |
0 |
0 |
2 |
3 |
4 |
28 |
Médecine personnalisée et prix des médicaments |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
17 |
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
20 |
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment |
0 |
0 |
0 |
0 |
1 |
3 |
9 |
50 |
Payment mechanism and GP self-selection: capitation versus fee for service |
0 |
0 |
0 |
0 |
1 |
2 |
8 |
47 |
Perception du lien entre mode de rémunération et comportement des médecins |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
26 |
Perception du lien entre mode de rémunération et comportement des médecins |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
26 |
Personalized medicine and drug prices |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
29 |
Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
40 |
Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
38 |
Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
23 |
Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
45 |
Physicians self selection of a payment mechanism: Capitation versus fee-for-service |
0 |
0 |
3 |
29 |
1 |
1 |
5 |
80 |
Physicians self selection of a payment mechanism: Capitation versus fee-for-service |
0 |
0 |
0 |
29 |
3 |
5 |
14 |
257 |
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
13 |
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
Physicians' balance billing, supplemental insurance and access to health care |
0 |
0 |
1 |
13 |
2 |
2 |
6 |
80 |
Physicians’ balance billing, supplemental insurance and access to health care |
0 |
0 |
0 |
27 |
1 |
1 |
4 |
111 |
Physicians’ balance billing, supplemental insurance and access to health care |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
42 |
Preferences for Demand versus Supply Side Cost-Sharing |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
12 |
Pricing and Welfare of Parallel Imports in the Pharmaceutical Industry |
0 |
0 |
1 |
163 |
0 |
2 |
6 |
433 |
Primary Care, Gatekeeping and Incentives |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
68 |
Regulation and Altruism |
0 |
0 |
1 |
29 |
4 |
7 |
17 |
40 |
Regulation and Altruism |
0 |
0 |
0 |
25 |
0 |
1 |
7 |
29 |
Regulation and altruism |
0 |
0 |
0 |
27 |
1 |
5 |
15 |
36 |
Regulation and altruism |
0 |
0 |
0 |
9 |
2 |
3 |
16 |
28 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
4 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
14 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
53 |
0 |
1 |
8 |
25 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
3 |
Research funding and price negotiation for new drugs |
0 |
0 |
1 |
44 |
0 |
0 |
5 |
9 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
15 |
Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
5 |
7 |
7 |
Treatment and referral decisions under different physician payment mechanisms |
0 |
0 |
0 |
38 |
1 |
2 |
8 |
99 |
Total Working Papers |
1 |
5 |
18 |
1,110 |
37 |
97 |
439 |
6,993 |